Cargando…
In Vitro and In Vivo Analysis of Indocyanine Green-Labeled Panitumumab for Optical Imaging—A Cautionary Tale
[Image: see text] Indocyanine green (IC-Green), the only FDA approved near-infrared (NIR) fluorophore for clinical use, is attractive to researchers for the development of targeted optical imaging agents by modification of its structure and conjugation to monoclonal antibodies (mAbs) or their fragme...
Autores principales: | Zhou, Yang, Kim, Young-Seung, Milenic, Diane E., Baidoo, Kwamena E., Brechbiel, Martin W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198103/ https://www.ncbi.nlm.nih.gov/pubmed/25243604 http://dx.doi.org/10.1021/bc500312w |
Ejemplares similares
-
In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers
por: Wong, Karen J, et al.
Publicado: (2011) -
Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab
por: Milenic, Diane E., et al.
Publicado: (2017) -
HER1-Targeted (86)Y-Panitumumab Possesses Superior Targeting Characteristics than (86)Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts
por: Nayak, Tapan K., et al.
Publicado: (2011) -
Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial
por: Milenic, Diane E., et al.
Publicado: (2015) -
Impact of α-Targeted Radiation Therapy on Gene Expression in a Pre-Clinical Model for Disseminated Peritoneal Disease when Combined with Paclitaxel
por: Yong, Kwon Joong, et al.
Publicado: (2014)